ArticleFrontiers in immunology2026
Comprehensive analysis based on tertiary lymphoid structures and tumor budding predicts survival rates in colorectal cancer patients with synchronous liver metastases.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Synchronous colorectal cancer liver metastasis (CRCLM) is closely associated with poor prognosis; however, the precise factors contributing to this adverse outcome remain uncertain. In the tumor microenvironment of CRCLM, tumor budding (TB) serves as a morphologic hallmark of invasive potential, while tertiary lymphoid structures (TLS) are indicative of organized anti-tumor immune contexture. This study aimed to integrate these biomarkers to predict the survival of patients with CRCLM. Methods: This multicenter retrospective study enrolled 107 patients with synchronous CRCLM who underwent curative resection for colorectal cancer. An external validation cohort including 30 patients with CRCLM were also employed. The density of TLS and the TB count were quantified via hematoxylin and eosin (H&E) staining and immunohistochemical (IHC) staining on primary tumor specimens. Relationships between clinicopathological data, overall survival (OS), and recurrence-free survival (RFS) were analyzed. The TLS/TB index was derived by integrating TLS and TB densities. The clinical role and prognostic value of the TLS/TB index in patients with CRCLM were analyzed, and a nomogram was constructed to predict the 3-year survival of patients. Results: High TLS density was significantly associated with prolonged overall survival (OS; p < 0.001) and recurrence-free survival (RFS; p< 0.001) in patients with CRCLM. Conversely, higher TB grade predicted a worse OS (p < 0.001) and RFS (p < 0.001). The TLS and TB exhibited a significant inverse correlation (r = -0.581, p < 0.001). The TLS/TB index demonstrated superior prognostic accuracy in the training cohort (AUC = 0.89) compared with histological differentiation (AUC = 0.70), TB grade (AUC = 0.85) and TLS density (AUC = 0.80), with consistent performance in the validation cohort. Calibration curves showed acceptable agreement between predicted and observed survival in both cohorts. Conclusion: These results demonstrated that tumor budding and tertiary lymphoid structures are inversely correlated in CRCLM. Furthermore, the TLS/TB-based nomogram may effectively enhanced the accuracy of prognosis prediction in patients with CRCLM, potentially facilitating the formulation of individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.